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Chronic obstructive pulmonary disease (COPD) is characterized by chronic local and systemic
inflammation, and increased oxidative stress. Changes in peripheral blood leukocyte counts or
in the fractions of leukocyte subsets might be implicated in the development of this disease. In
this study, increased monocyte fraction was observed in COPD non-smokers. In light COPD
smokers, the fraction of neutrophils was significantly increased along with significantly de-
creased lymphocyte fraction and lung function parameters. Heat shock proteins (Hsps) could
stimulate antioxidant defence of cells by decreasing intracellular levels of reactive oxygen par-
ticles (ROS) and by neutralizing toxic effects of oxidized proteins. This study showed that the
expression of Hsps in leukocytes was influenced by health and smoking status. Hsp70 and
Hsp27 were significantly decreased in COPD ex-smokers and healthy smokers, but the most
striking suppression in Hsps expression was detected in COPD smokers. It is suggested that
this decline in Hsps intracellular levels could be implicated in the pathogenesis of COPD.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is cha-
racterized by slowly progressive and poorly reversible de-
velopment of airflow limitation and by abnormal inflam-
matory response in the airways. COPD is now recogniz-
ed as a major and increasing global health problem, and
is predicted to be the third most common cause of death
and the fifth most common cause of disability in the world
by the year 2020.1 Pathological hallmarks of COPD in-
clude chronic obstructive bronchitis with fibrosis and ob-
struction of small airways, emphysema with destruction
of lung parenchyma, loss of lung elasticity and obstruc-
tion of peripheral airways.2,3 The critical role of the lo-
cal inflammatory process in the pathogenesis of COPD
is recognized and generally accepted, and it is associated
with the influx of neutrophils into the airway lumen and
increased macrophage and T lymphocyte numbers in the
airway wall. However, less is known about the so called
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low-grade systemic inflammation present in COPD. Many
studies have reported changes in oxidative status, and le-
vels of inflammatory cells and mediators in the circula-
tion of COPD patients.3,4 Cigarette smoking is the major
etiological factor responsible for COPD and more than
90 % of COPD patients are smokers. However, only
15–20 % of chronic smokers develop COPD. These ob-
servations indicate that additional risk factors, possibly
genetic, contribute to the development and the severity
of COPD.4–6 There is now considerable evidence of in-
creased oxidative stress in smokers and in COPD pa-
tients.7–9 Cigarette smoke is a complex mixture of more
than 4700 chemical compounds, including high concen-
trations of free radicals and other oxidants. In addition,
activated circulating neutrophils, monocytes and eosino-
phils release reactive oxygen species (ROS). Oxidative
burden is also propagated by increased ROS production
from alveolar macrophages and epithelial cells.8,10 ROS
may affect the target cells directly or indirectly, via acti-
vation of signal transduction pathways and via formation
of oxidized mediators.3,7,8 Inappropriate activation of sig-
nalling pathways could occur during acute and chronic
oxidative stress as a result of protein misfolding, protein
aggregation, or disruption of regulatory complexes.
The network of heat shock proteins (Hsps) represents
an emerging paradigm for the coordinated, multistep re-
gulation of apoptotic signalling events to provide protec-
tion from damaging stimuli and to facilitate cellular re-
covery. These proteins act as molecular chaperones by
assisting the correct folding of nascent and stress-accu-
mulated misfolded proteins, and by preventing their ag-
gregation. Hsp synthesis is tightly regulated at the trans-
criptional level by heat shock transcription factors (HSFs),
especially by HSF-1. In resting cells, HSF-1 is a mono-
mer; however, active HSF-1 exists as a trimer and binds
to the heat shock elements (HSEs) present in the promo-
ters of the heat shock-inducible genes.11,12
It was suggested that circulating neutrophils might be
implicated in the pathogenesis of COPD, but the role of
other peripheral blood cell types in COPD is still unclear.
In this study, we investigated the changes in total peri-
pheral blood leukocyte counts, fractions of leukocyte sub-
sets (neutrophils, eosinophils, basophils, monocytes and
lymphocytes) and lung function parameters (FEV1, FEV1/
FVC) in patients with COPD and in healthy volunteers.
They were all men with different smoking histories. Chro-
nic inflammation and increased oxidative stress play a
major role in the pathogenesis of COPD. It has been
shown that Hsps can modulate the cell’s immune respon-
se and inflammatory response. In particular, it has been
demonstrated that both Hsp27 and Hsp70 control inflam-
mation by regulating the expression of the pro- and anti-in-
flammatory genes. In addition, these proteins, especially
Hsp27, could protect cells from oxidative damage by de-
creasing ROS production, neutralizing the toxic effects
of oxidized proteins, and by affecting cellular glutathione
levels. Thus, we assessed the level of Hsp27 and Hsp70
expression in the leukocytes of COPD patients and
healthy volunteers, and we hypothesized that their ex-
pression would be affected by the person’s health status
and smoking history.
EXPERIMENTAL
Subjects
The study included 28 male COPD subjects (11 smokers, 9
ex-smokers, 8 non-smokers) and 42 healthy male subjects
(15 smokers, 13 ex-smokers, 14 non-smokers) of similar
age (50–70 years old). Participants had no history of bron-
chial asthma, respiratory tract infectious diseases 1 month
prior to the study, no cardiac, renal, hepatic, gastrointestinal
or endocrine diseases. Control subjects were taking no me-
dications. COPD patients were receiving bronchodilators
only, and no inhaled or oral corticosteroids. Their medica-
tion therapy consisted of a combination of long-acting (sal-
butamol) and short-acting (salmeterol) b2-agonists as need-
ed, an anticholinergic (ipatropium bromide) and a xanthine
preparation (theophylline). All patients were considered to
be clinically stable because none of them had required me-
dical attention and/or any change in their regular therapy
during the previous 3 months. COPD patients had moderate
(n = 11) or severe to very severe COPD (n = 17) according
to the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD). The study protocol was approved by the Eth-
ics Committee of the University Hospital for Lung Diseases
Jordanovac. All participants gave their written consent after
being fully informed of the nature, characteristics, risks,
and potential benefits of the study.
Spirometry Measurements
Before starting the measurements, the patient’s height and
weight were measured. Testing was performed in the seat-
ing or standing position. After applying nose clips, the sub-
ject was instructed to take a full inspiration, and then ex-
hale without hesitation through a mouthpiece into the spiro-
meter (MasterLab Pro Body version 3.1, E. Jaeger, Wurzburg,
Germany) as forcefully and completely as possible, but at least
for six seconds. The test was repeated a minimum of three
times, and a maximum of eight times, until two reproducible
efforts were obtained. The two largest forced vital capacities
(FVC) and forced expiratory volumes in one second (FEV1)
had to show <5 % variability. After spirometry measurements
were taken according to the standard procedure, the patient
inhaled 400 mg of salbutamol from a metered dose inhaler.
After 15–30 minutes, spirometry was repeated with three
measurements, and the highest FEV1 value was recorded.
Before testing, regularly prescribed bronchodilators were
withheld for 6 hours for inhaled short-acting b2-agonists,
12 hours for long-acting b2-agonists, 6 hours for inhaled
anticholinergics, 12 hours for short-acting theophylline pre-
parations, and 24 hours for long-acting theophylline prepa-
rations. The bronchodilatatory test was considered negative
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if the FEV1 value after salbutamol was less than 200 mL
and/or 12 % of that before testing. FEV1 was expressed in
percents with respect to referent values which were used
according to the lung parameter standard of the European
Community for Coal and Steel (ECCS).13
Blood Sampling
Peripheral blood was collected from all subjects after an
overnight fast into tubes containing lithium heparin as anti-
coagulant. Total leukocyte blood counts and leukocyte dif-
ferential blood counts were determined using an automated
haematology analyzer (Sysmex KX-21N). The fractions of
leukocyte subsets (neutrophils, eosinophils, basophils, mo-
nocytes and lymphocytes) were expressed in percents.
Leukocyte Isolation
Leukocytes were isolated according to the method of Percy
and Brady.14 Whole blood and dextran (50 g of dextran in 1
dm–3 of 120 mmol dm–3 NaCl solution) were mixed in a
5:1 ratio and left to sediment for one hour at room tempera-
ture. The supernatant, containing leukocytes, was separated
from the sediment containing erythrocytes. The supernatant
was centrifuged at 500 g for 10 minutes at 4 °C. The sedi-
ment was suspended in 150 mmol dm–3 NaCl solution, ery-
throcyte impurities were removed by hypotonic lysis, and
the sample was centrifuged for 10 minutes at 4 °C. This pu-
rifying procedure was repeated three times. Purified leuko-
cytes obtained from 5 mL of whole blood were suspended
in 150 mL of ice-cold whole-cell lysis buffer (50 mmol
dm–3 Tris-HCl pH = 8.0, 137 mmol dm–3 NaCl, 1 % Non-
ident P-40, 10 % glycerol, and a Complete Protease Inhibi-
tor Cocktail Tablet).
Leukocyte Lysis
Leukocyte lysates were prepared by repeated freezing/thaw-
ing procedures in addition to sonication, and finally cell ly-
sates were centrifuged at 25000 g for 20 minutes at 4 °C.
Protein concentration was determined by the method of Low-
ry et al.15 Samples were denatured by boiling for 3 minutes
with 6x Laemmli sample buffer (0.375 mol dm–3 Tris-HCl
pH = 6.8, 12 g/100 mL SDS, 3 % glycerol, 0.2 g/100 mL
bromophenol blue, 12 % b-mercaptoethanol, in distilled
water) at 4:1 dilution.
Western Blotting
50 mg of total protein was loaded for each sample onto a 12 %
polyacrylamide gel, usually run at 100 V. Transfer onto the
nitrocellulose membrane was conducted at 250 mA for 90
minutes. Membranes were blocked for one hour with block-
ing buffer containing 1 g/100 mL BSA and 1 g/100 mL
chicken egg albumin in TBS+T (25 mmol dm–3 Tris pH =
7.6, 150 mmol dm–3 NaCl, 0.05 % Tween 20). Membranes
were probed overnight at 4 °C with anti-Hsp27 (Stressgen,
Biotechnologies) diluted 1:5000 in blocking buffer, anti-
Hsp70 (Stressgen, Biotechnologies) diluted 1:1000 in block-
ing buffer or anti-actin (Sigma) diluted 1:1000 in blocking
buffer. A horseradish peroxidase-conjugated secondary an-
tibody diluted 1:4000 in 5 % low fat milk in TBS+T was
utilized to allow detection of the appropriate bands using
enhanced chemiluminescence reagent (ECLTM Western
Blotting Detection Reagents, Amersham Biosciences) and
film (Lumi-Film Chemiluminescent Detection film, Roche).
Membranes were stripped by incubating at 65 °C for half
an hour in stripping buffer (100 mmol dm–3 b-mercapto-
ethanol, 2 g/100 mL SDS and 62.5 mmol dm–3 Tris-HCl pH
= 6.7). All experiments were conducted at least three times.
Films were developed and scanned, and densitometry mea-
surements were performed using the ScionImage software
for Windows (Scion Corporation).
Statistical Analysis
Analyses were performed using the Sigmastat software for
Windows, version 3.5 (Systat Software Inc.). Variables were
all expressed as median (interquartile range) and tested for
normality using the Kolmogorov-Smirnov test. The t-test and
Mann-Whitney rank sum test were used for between-group
difference testing of parametric and nonparametric data, re-
spectively. Differences between multiple groups were test-
ed using the one-way ANOVA. Relationships between pairs
of variables were tested using Spearman’s rank correlation.
For Western blot analysis, statistical significance was deter-
mined by Student’s t-test, and data were expressed as mean
± SD. Values of P<0.05 were considered statistically sig-
nificant.
RESULTS
White Blood Cells and Lung Function Parameters
in COPD Patients and in Healthy Subjects
Cigarette smoking is known to increase neutrophil blood
counts and is negatively associated with postbronchodi-
lator FEV1.
7,16 We therefore wanted to explore changes
in total peripheral blood leukocyte counts, fractions of
leukocyte subsets and lung function parameters in COPD
patients and in healthy control subjects subdivided ac-
cording to their smoking history (Table I). In COPD pa-
tients, a statistically significant difference in monocyte
fraction was observed between ex-smokers and non-smo-
kers. On the other hand, healthy smokers had significantly
higher total leukocyte counts than ex-smokers and non-
smokers.
To further study the influence of cigarette smoking
on peripheral white blood cells and lung function, we have
subdivided COPD and healthy smokers and ex-smokers
in two groups according to the median value for daily
cigarette consumption: light smokers (daily cigarette
consumption < 22, Table II) and heavy smokers (daily
cigarette consumption ³ 22, Table III). Light COPD
smokers had a significantly higher neutrophil fraction and
a significantly lower lymphocyte fraction, FEV1 (expressed
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TABLE II. Total leukocyte counts, fractions of leukocyte subtypes, and lung function parameters in light COPD and healthy smokers(a)
Daily cigarette consumption < 22
Total COPD
(n = 12)
Total healthy
(n = 13)
COPD smokers
(n = 6)
Healthy smokers
(n = 10)
COPD ex-smokers
(n = 6)
Healthy ex-smokers
(n = 3)
Total leukocyte
counts / 109 dm–3
6.9
(5.3–8.2)
6.9
(6.5–7.7)
6.9
(6.5–7.3)
7.0
(6.6–7.7)
6.7
(5.2–8.2)
5.4
(4.7–8.4)
Neutrophils / % 69.5(b)
(63.0–76.5)
58.0
(55.8–61.3)
71.5(b)
(69.0–77.0)
59.0
(56.0–62.0)
64.5(c)
(63.0–76.0)
57.0
(55.5–59.3)
Eosinophils / % 1.5
(1.0–2.0)
3.0
(1.0–3.0)
1.0
(1.0–2.0)
2.0
(1.0–3.0)
2.0
(1.0–2.0)
3.0
(1.5–3.0)
Lymphocytes / % 26.0(b)
(17.0–29.5)
35.0
(33.0–37.3)
24.5(b)
(17.0–29.0)
35.5
(34.0–38.0)
27.0
(16.0–30.0)
34.0
(30.0–35.5)
Monocytes / % 5.0
(4.0–5.5)
4.0
(2.0–5.8)
4.0
(3.0–5.0)
3.0
(2.0–5.0)
5.0
(5.0–6.0)
8.0
(5.0–9.5)
FEV1 / %
(d) 45.9(b)
(42.2–53.3)
99.0
(89.8–111.0)
53.3(b)
(40.7–61.0)
100.5
(90.0–114.0)
44.5(b)
(43.7–46.7)
98.0
(91.3–107.0)
(FEV1/FVC) / % 59.9
(b)
(51.8–65.0)
82.0
(74.5–85.0)
57.4(b)
(45.7–65.1)
82.5
(73.0–85.0)
62.9(b)
(53.6–64.9)
82.0
(79.8–87.3)
(a)Fraction of basophiles was unchanged and close to zero for all conditions tested. Total COPD = total COPD smokers and ex-smokers, Total
healthy = total healthy smokers and ex-smokers; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity. Data are presented as
median and interquartile range in parentheses. Differences between total COPD subjects and total healthy subjects, COPD and healthy smokers,
and COPD and healthy ex-smokers were tested by the t-test and Mann-Whitney rank sum test for parametric and nonparametric data, respectively.
(b)Significant difference between the groups (total COPD and total healthy; COPD smokers and healthy smokers; COPD ex-smokers and healthy
ex-smokers), P<0.05.
(c)Trend towards significance, 0.05<P<0.1.
(d)With respect to referent, predicted value.
TABLE I. Total leukocyte counts, fractions of leukocyte subtypes, and lung function parameters in COPD patients and healthy individuals
subdivided according to their smoking histories(a)
COPD patients (n = 28)
P
Healthy subjects (n = 42)
PSmokers
(n = 11)
Ex-smokers
(n = 9)
Non-smokers
(n = 8)
Smokers
(n = 15)
Ex-smokers
(n = 13)
Non-smokers
(n = 14)
Total leukocyte
counts / 109 dm–3
7.3
(6.5–8.7)
7.0
(5.1–8.1)
5.5
(5.1–8.7)
0.338 7.1
(6.7–7.8)
5.3
(4.9–5.9)
5.6
(4.9–6.9)
£0.001(b),(c)
Neutrophils / % 69.0
(60.8–72.3)
63.0
(62.0–68.5)
59.5
(56.0–70.5)
0.611 58.0
(52.8–61.8)
58.0
(54.3–61.3)
56.0
(54.0–60.0)
0.979
Eosinophils / % 1.0
(1.0–3.0)
2.0
(1.8–2.3)
0.0
(0.0–2.5)
0.270 3.0
(1.0–3.0)
3.0
(1.0–3.0)
0.5
(0.0–2.0)
0.156
Lymphocytes / % 24.0
(19.8–29.8)
27.0
(24.3–30.3)
31.5
(17.5–35.5)
0.926 36.0
(31.8–38.8)
33.0
(29.8–36.3)
38.5
(31.0–41.0)
0.813
Monocytes / % 6.0
(4.0–7.8)
5.0
(5.0–6.0)
8.0
(6.5–8.5)
0.069(d) 4.0
(2.0–6.5)
5.0
(4.0–7.3)
5.0
(3.0–7.0)
0.495
FEV1 / %
(e) 52.6
(34.9–55.5)
45.0
(43.0–47.0)
47.1
(40.6–58.9)
0.630 99.0
(87.8–115)
112
(96.5–115)
103.0
(94.0–109)
0.515
(FEV1/FVC) / % 56.4
(48.4–59.8)
64.3
(53.2–66.4)
61.1
(56.9–66.7)
0.116 82.0
(75.0–84.8)
82.0
(77.3–89.0)
81.0
(79.0–84.0)
0.643
(a)Fraction of basophiles was unchanged and close to zero for all conditions tested. FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity. Data are presented as median and interquartile range in parentheses. Differences between multiple groups were tested using one-way
ANOVA, and between two groups by the t-test and Mann-Whitney rank sum test for parametric and nonparametric data, respectively.
(b)Significant difference between the multiple groups (COPD smokers, ex-smokers and non-smokers; healthy smokers, ex-smokers and non-smok-
ers), P<0.05.
(c)Significant difference between healthy smokers and healthy ex-smokers, and between healthy smokers and healthy non-smokers, P<0.05.
(d)Significant difference between COPD ex-smokers and COPD non-smokers, P<0.05.
(e)With respect to referent, predicted value.
in percents with respect to referent values) and FEV1/FVC
ratio (expressed in percents) compared to light healthy
smokers. On the other hand, in light COPD ex-smokers
only a significant decrease in FEV1 and FEV1/FVC was
observed compared to light healthy ex-smokers. Heavy
COPD smokers had a significantly lower FEV1 and
FEV1/FVC than heavy healthy smokers, while only FEV1
was significantly reduced in heavy COPD ex-smokers as
compared to healthy ex-smokers.
Expression of Hsp70 and Hsp27 in Leukocytes of
COPD Patients and in Healthy Subjects
It has been shown that an increase in Hsps expression
protects cells from various kinds of stressors.17,18 We as-
sessed the level of expression of Hsp70 and Hsp27 in
the peripheral blood leukocytes of COPD patients and
healthy individuals (Figures 1 and 2). Expression of both
Hsp70 and Hsp27 was dependent on health status (sub-
jects with or without COPD) and smoking status (smo-
kers, ex-smokers and non-smokers). Expression of Hsp70
and Hsp27 was significantly decreased in COPD ex-smo-
kers and healthy smokers, but the most striking suppres-
sion of Hsps expression was detected in COPD smokers
as compared to healthy non-smokers.
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TABLE III. Total leukocyte counts, fractions of leukocyte subtypes, and lung function parameters in heavy COPD and healthy smokers(a)
Daily cigarette consumption ³ 22
Total COPD
(n = 8)
Total healthy
(n = 15)
COPD smokers
(n = 5)
Healthy smokers
(n = 5)
COPD ex-smokers
(n = 3)
Healthy ex-smokers
(n = 10)
Total leukocyte
counts / 109 dm–3
7.6(b)
(6.3–8.6)
5.8
(5.0–6.8)
8.5
(7.3–9.6)
7.7
(6.7–8.1)
7.0(c)
(5.4–7.5)
5.2
(5.0–5.8)
Neutrophils / % 63.0
(59.5–66.0)
58.0
(50.5–61.8)
63.0
(56.8–67.5)
55.0
(47.0–62.5)
63.0
(60.0–64.5)
58.5
(52.0–62.0)
Eosinophils / % 2.5
(1.5–4.0)
3.0
(1.3–3.8)
3.0
(0.8–3.5)
3.0
(1.8–5.8)
2.0
(2.0–4.3)
3.0
(1.0–3.0)
Lymphocytes / % 28.5(c)
(23.0–30.5)
33.0
(30.3–38.5)
24.0
(21.3–33.8)
36.0
(28.0–42.5)
30.0
(27.8–30.8)
33.0
(30.0–37.0)
Monocytes / % 7.0(c)
(5.5–8.5)
5.0
(4.0–7.0)
8.0
(7.0–9.3)
7.0
(3.5–8.3)
5.0
(5.0–5.8)
5.0
(4.0–7.0)
FEV1 / %
(d) 43.0(b)
(33.1–53.8)
112.0
(92.5–118.5)
33.2(b)
(32.5–53.8)
94.0
(85.3–126.0)
45.0(b)
(42.0–52.2)
112.5
(112.0–117.0)
(FEV1/FVC) / % 55.3
(b)
(48.9–63.2)
82.0
(75.8–87.8)
43.9(b)
(48.5–59.1)
82.0
(78.0–85.0)
66.2
(55.4–78.3)
82.0
(75.0–89.0)
(a)Fraction of basophiles was unchanged and close to zero for all conditions tested. Total COPD = total COPD smokers and ex-smokers, Total
healthy = total healthy smokers and ex-smokers; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity. Data are presented as
median and interquartile range in parentheses. Differences between total COPD subjects and total healthy subjects, COPD and healthy smokers,
and COPD and healthy ex-smokers were tested by the t-test and Mann-Whitney rank sum test for parametric and nonparametric data, respectively.
(b)Significant difference between the groups (total COPD and total healthy; COPD smokers and healthy smokers; COPD ex-smokers and healthy
ex-smokers), P<0.05.
(c)Trend towards significance, 0.05<P<0.1.
(d)With respect to referent, predicted value.
Figure 1. Expression of Hsp70 and Hsp27 in the peripheral blood
leukocytes of COPD patients (a) and healthy individuals (b).
Participants were subdivided according to their smoking history in
three groups: smokers (s; lines 1 and 2), ex-smokers (ex-s; lines 3
and 4) and non-smokers (non-s; lines 5 and 6). Western blot ana-
lysis was performed as described in Experimental. Representative
blots for Hsp70 and Hsp27 expression in the leukocytes of COPD
patients (a) and healthy individuals (b) from three independent
experiments are shown. b-actin was detected to ensure that equal
amounts of proteins were loaded for each sample.
DISCUSSION
COPD is characterized by chronic local and systemic in-
flammation, and increased oxidative stress. Cigarette
smoking is the major etiological factor responsible for
COPD and, so far, smoking cessation is the only inter-
vention able to reduce the progression of COPD.19 How-
ever, several studies have shown that airway inflamma-
tion persists even after smoking cessation.20,21 Neutro-
phils play an important role in the pathogenesis of
airway inflammation in COPD due to their ability to re-
lease a number of mediators such as elastases, metallo-
proteases and oxygen-derived radicals which promote
tissue inflammation and damage.22 Cigarette smoking is
known to increase neutrophil blood counts and to cause
sequestration of the neutrophils in the lung capillaries by
decreasing their deformability.23 In addition, epidemio-
logical studies have shown a relationship between the
number of circulating neutrophil and FEV1 and between
smoking and FEV1.
7,16 In contrast to neutrophils, the
possible association between other peripheral blood cell
types and COPD is less clearly understood. In our study,
increased monocyte fraction was observed in COPD
non-smokers. In »light« COPD smokers (daily cigarette
consumption < 22), the fraction of neutrophils was sig-
nificantly increased along with a significantly decreased
lymphocyte fraction and lung function parameters. On
the other hand, we could not detect any significant chan-
ge in leukocyte subtypes in »heavy« COPD smokers
(daily cigarette consumption ³ 22), and only FEV1 and
FEV1/FVC were significantly decreased in those sub-
jects. Unfortunately, due to the small number of COPD
and healthy participants, it would be inappropriate to in-
fer from these observations that any peripheral blood
leukocyte subtype is necessarily actively involved in the
pathogenesis of COPD.
In determining prophylactic and/or therapeutic strate-
gies against COPD and other human diseases, it is rea-
sonable to regard the intracellular molecules that might
regulate their mechanisms, such as heat shock proteins
(Hsps), as appropriate targets. There is increasing evi-
dence that Hsps may function at multiple checkpoints in
the apoptotic signalling pathway, and these proteins
could increase the antioxidant defence of cells by de-
creasing the intracellular levels of ROS and by neutrali-
zing the toxic effects of oxidized proteins.17,24,25 Imbal-
ance between oxidants and antioxidants is considered to
play a role in the pathogenesis of COPD.
Our data show that the expression of both Hsp70 and
Hsp27 in the peripheral blood leukocytes is down-regulat-
ed in COPD ex-smokers, healthy smokers and especially
in COPD smokers, which could further promote oxida-
tive burden within the cell. This is in agreement with the
results presented by Zhao and colleagues, who reported
a decrease in Hsp70 mRNA and Hsp70 protein levels in
the lymphocytes of COPD patients.26 Some studies refer
to the reduced transcriptional activity and binding of HSF
to the HSE as being the cause of the decrease in Hsp pro-
duction.27,28 It was demonstrated that mitogen-activated
protein kinases ERK and JNK could bind to and phos-
phorylate HSF-1 at distinct sites, leading to suppression
of its transcriptional activity.18,25,29 On the other hand,
Hsp70 negatively regulates stress kinases JNK and p38
MAPK.30 However, various stressful conditions cause
depletion of free cellular Hsp70 by accumulated abnor-
mal proteins, which induce activation of stress kinases.30
Indeed, we have observed a strong activation of JNK and
p38 MAPKs in the contexts where Hsps expression was
decreased, e.g., in COPD smokers, COPD ex-smokers and
in healthy smokers (unpublished data).
Decreased intracellular Hsps concentration could
also reflect their increased release from the cell. Extra-
cellular Hsps were present in the peripheral circulation
of healthy individuals; however, elevated levels can be
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Figure 2. Graphic presentation of the levels of Hsp70 (a) and
Hsp27 (b) expression in the peripheral blood leukocytes of COPD
patients (1, 2, 3) and healthy individuals (4, 5, 6). Participants were
subdivided according to their smoking history in three groups:
smokers (1, 4), ex-smokers (2, 5) and non-smokers (3, 6). Data
were expressed as mean ± SD. Densitometric values of Hsps levels
were normalized to the housekeeping protein b-actin. The norma-
lized expression of Hsps in the leukocytes of healthy non- smokers
was taken as 1. Asterisk denotes significant change compared
to healthy non-smokers. Differences were considered significant at
P<0.05.
found in various disease conditions, including inflamma-
tion, bacterial and viral infection, atherosclerosis, hyper-
tension and renal disease.17,31,32 Although the exact me-
chanism by which intracellular Hsps leave cells is still
incompletely understood, it has been suggested that
Hsps are released by both passive (necrotic) and active
(physiological) mechanisms.17,31–36
Extracellular Hsp27 and Hsp72 possess potent cha-
perone and cytokine activity, a term now referred to as
the chaperokine ability of Hsps.31, 37 Exogenously added
Hsps activate signal transduction cascades, leading to
the stimulation of an immune response by inducing the
production and release of various cytokines,37–39 which
could lead to continuous propagation of inflammation
observed in COPD. Therefore, Hsps might become re-
cognized as attractive pharmacological targets for the treat-
ment of chronic inflammatory diseases, including COPD.
In conclusion, in this study we have observed
down-regulation of the expression of Hsp70 and Hsp27
in the peripheral blood leukocytes from patients with
COPD (smokers and ex-smokers) and from healthy smo-
kers. We suggest that this decline in the Hsps intracel-
lular levels could be implicated in the pathogenesis of
COPD. A challenge to our future research is to determi-
ne the levels of Hsp27 and Hsp70 in sera of large groups
of COPD patients carefully selected according to disease
severity, smoking history and receiving therapy, and to
test the hypothesis that extracellular Hsps may act as an
effective danger signal to the immune system.
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SA@ETAK
Promjene u udjelu pojedinih tipova leukocita u krvi i u ekspresiji proteina
toplinskoga {oka u kroni~noj opstrukcijskoj plu}noj bolesti
Lada Rumora, Lara Milevoj, Sanja Popovi}-Grle, Karmela Bari{i}, Ivana ^epelak
i Tihana @ani} Grubi{i}
Temeljne su karakteristike kroni~ne opstrukcijske plu}ne bolesti (KOPB; engl. Chronic Obstructive Pul-
monary Disease, COPD) kroni~na upala i oksidacijski stres. Mogu}e je da promjene u broju ukupnih leukocita
u krvi ili u pojedinim tipovima leukocita utje~u na razvoj ove bolesti. U istra`ivanju su utvr|eni povi{eni mono-
citi kod nepu{a~a s KOPB-om. S druge strane, kod pu{a~a s KOPB-om koji su dnevno pu{ili do 22 cigarete
opa`eni su povi{eni neutrofili i sni`eni limfociti te sni`eni parametri koji upu}uju na funkciju plu}a. Proteini
toplinskoga {oka (engl. Heat shock proteins, Hsp) djeluju na oksidirane proteine tako da neutraliziraju njihovo
toksi~no djelovanje, a smanjuju i koncentraciju reaktivnih kisikovih spojeva u stanici. U na{em se ispitivanju
pokazalo da ekspresija Hsp-a ovisi i o zdravstvenom stanju ispitanika i o tome pu{i li. Razine Hsp70 i Hsp27
zna~ajno su potisnute kod biv{ih pu{a~a s KOPB-om i kod zdravih pu{a~a, a osobito kod pu{a~a s KOPB-om.
Rezultati ovih istra`ivanja upu}uju na mogu}nost da su Hsp70 i Hsp27 upleteni u patogenezu KOPB-a.
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